

D¹ 122. (Amended) The recombinant RSV of claim 63, formulated in a dose of 10^3 to 10^6 PFU of attenuated virus.

D² 128. (Amended) An immunogenic composition effective to elicit an immune response in a mammalian subject directed against RSV, which comprises an immunologically sufficient amount of the recombinant RSV of claim 63 in a physiologically acceptable carrier.

D³ 129. (Amended) The immunogenic composition of claim 128, formulated in a dose of 10^3 to 10^6 PFU of the attenuated RSV.

130. (Amended) The immunogenic composition of claim 128, formulated for administration to the upper respiratory tract by spray, droplet or aerosol.

D⁴ 131. (Amended) The immunogenic composition of claim 128, wherein the recombinant RSV elicits an immune response against human RSV A, human RSV B, or both.